Laminar Pharma Receives Rare Pediatric Disease Designation from the U.S. FDA for LAM561
Laminar Pharmaceuticals S.A., empresa biotecnológica española en fase clínica centrada en el desarro...
11 September, 2023Laminar Pharmaceuticals S.A., empresa biotecnológica española en fase clínica centrada en el desarro...
11 September, 2023Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process....
10 August, 2022The Spanish Bioindustry Association (AseBio), where Laminar Pharma is a member, has published its la...
13 July, 2021